Regulations.gov document
Reference 13 CCP guidance - Convalescent plasma with a high level of virus-specific…
Supporting & Related Material · FDA-2024-D-2442 · posted Jul 25, 2024
Key facts
| Document ID | FDA-2024-D-2442-0015 |
|---|---|
| Title | Reference 13 CCP guidance - Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2024-D-2442 |
| Posted | Jul 25, 2024 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: